The Experts below are selected from a list of 21672 Experts worldwide ranked by ideXlab platform

Gunnar Regenbrecht - One of the best experts on this subject based on the ideXlab platform.

  • Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on Clinical Global Impression in chronic schizophrenia.
    Psychiatry Research-neuroimaging, 2010
    Co-Authors: Joachim Cordes, Johanna Thünker, Marcus W. Agelink, M. Arends, Arian Mobascher, Thomas Wobrock, Thomas Schneider-axmann, Jürgen Brinkmeyer, Margarethe Mittrach, Gunnar Regenbrecht
    Abstract:

    Abstract We conducted a randomized, sham-controlled repetitive transcranial magnetic stimulation (rTMS) study in chronic schizophrenia in-patients ( n =35) to evaluate the therapeutic efficacy of 10 Hz stimulation. Patients, who were on stable antipsychotic treatment, were randomly assigned to the active or sham condition. In the active rTMS group, ten sessions with a total of 10,000 stimuli were applied over the left dorsolateral prefrontal cortex at 110% of motor threshold. The sham group received corresponding sham stimulation. Clinical improvement was measured by the Clinical Global Impression scale (primary outcome measure), the Global Assessment of Functioning Scale (GAF) and the Positive and Negative Symptom Scale (PANSS; secondary outcome measures). Between-group comparisons revealed no significant differences in Clinical outcome variables. Only a subgroup of patients with pronounced negative symptoms developed some Clinical improvement as indicated by significant changes in the GAF-scale. Besides there is some evidence for a more favourable Clinical outcome within this subgroup after rTMS in the CGI-S and PANSS negative scale, too. In line with earlier investigations, our results suggest a moderate — potentially Clinically relevant — treatment effect of prefrontal 10 Hz rTMS stimulation in chronic patients. However, in our study this beneficial effect was restricted to subjects with pronounced negative symptoms. Clinical trial registration information ClinicalTrial.gov Identifier: NCT00169689, http://www.Clinicaltrials.gov.

  • Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on Clinical Global Impression in chronic schizophrenia.
    Psychiatry research, 2010
    Co-Authors: Joachim Cordes, Johanna Thünker, Marcus W. Agelink, M. Arends, Arian Mobascher, Thomas Wobrock, Thomas Schneider-axmann, Jürgen Brinkmeyer, Margarethe Mittrach, Gunnar Regenbrecht
    Abstract:

    We conducted a randomized, sham-controlled repetitive transcranial magnetic stimulation (rTMS) study in chronic schizophrenia in-patients (n=35) to evaluate the therapeutic efficacy of 10 Hz stimulation. Patients, who were on stable antipsychotic treatment, were randomly assigned to the active or sham condition. In the active rTMS group, ten sessions with a total of 10,000 stimuli were applied over the left dorsolateral prefrontal cortex at 110% of motor threshold. The sham group received corresponding sham stimulation. Clinical improvement was measured by the Clinical Global Impression scale (primary outcome measure), the Global Assessment of Functioning Scale (GAF) and the Positive and Negative Symptom Scale (PANSS; secondary outcome measures). Between-group comparisons revealed no significant differences in Clinical outcome variables. Only a subgroup of patients with pronounced negative symptoms developed some Clinical improvement as indicated by significant changes in the GAF-scale. Besides there is some evidence for a more favourable Clinical outcome within this subgroup after rTMS in the CGI-S and PANSS negative scale, too. In line with earlier investigations, our results suggest a moderate - potentially Clinically relevant - treatment effect of prefrontal 10 Hz rTMS stimulation in chronic patients. However, in our study this beneficial effect was restricted to subjects with pronounced negative symptoms. ClinicalTrial.gov Identifier: NCT00169689, http://www.Clinicaltrials.gov. Copyright 2009 Elsevier Ltd. All rights reserved.

Bruno Falissard - One of the best experts on this subject based on the ideXlab platform.

  • The improved Clinical Global Impression Scale (iCGI): development and validation in depression
    BMC Psychiatry, 2007
    Co-Authors: Alane Kadouri, Emmanuelle Corruble, Bruno Falissard
    Abstract:

    Background The Clinical Global Impression scale (CGI) is frequently used in medical care and Clinical research because of its face validity and practicability. This study proposes to improve the reliability of the Clinical Global Impression (CGI) scale in depressive disorders by the use of a semi-standardized interview, a new response format, and a Delphi procedure. Methods Thirty patients hospitalised for a major depressive episode were filmed at T1 (first week in hospital) and at T2 (2 weeks later) during a 5' specific interview. The Hamilton Depressive Rating Scale and the Symptom Check List were also rated. Eleven psychiatrists rated these videos using either the usual CGI response format or an improved response format, with or without a Delphi procedure. Results The new response format slightly improved (but not significantly) the interrater agreement, the Delphi procedure did not. The best results were obtained when ratings by 4 independent raters were averaged. In this situation, intraclass correlation coefficients were about 0.9. Conclusion The Clinical Global Impression is a useful approach in psychiatry since it apprehends patients in their entirety. This study shows that it is possible to quantify such Impressions with a high level of interrater agreement.

  • The improved Clinical Global Impression Scale (iCGI): development and validation in depression.
    BMC psychiatry, 2007
    Co-Authors: Alane Kadouri, Emmanuelle Corruble, Bruno Falissard
    Abstract:

    The Clinical Global Impression scale (CGI) is frequently used in medical care and Clinical research because of its face validity and practicability. This study proposes to improve the reliability of the Clinical Global Impression (CGI) scale in depressive disorders by the use of a semi-standardized interview, a new response format, and a Delphi procedure. Thirty patients hospitalised for a major depressive episode were filmed at T1 (first week in hospital) and at T2 (2 weeks later) during a 5' specific interview. The Hamilton Depressive Rating Scale and the Symptom Check List were also rated. Eleven psychiatrists rated these videos using either the usual CGI response format or an improved response format, with or without a Delphi procedure. The new response format slightly improved (but not significantly) the interrater agreement, the Delphi procedure did not. The best results were obtained when ratings by 4 independent raters were averaged. In this situation, intraclass correlation coefficients were about 0.9. The Clinical Global Impression is a useful approach in psychiatry since it apprehends patients in their entirety. This study shows that it is possible to quantify such Impressions with a high level of interrater agreement.

  • The Improved Clinical Global Impression Scale (iCGI): development and validation in depression.
    BMC Psychiatry, 2007
    Co-Authors: Alane Kadouri, Emmanuelle Corruble, Bruno Falissard
    Abstract:

    BACKGROUND: The Clinical Global Impression scale (CGI) is frequently used in medical care and Clinical research because of its face validity and practicability. This study proposes to improve the reliability of the Clinical Global Impression (CGI) scale in depressive disorders by the use of a specific interview, a new response format, and a Delphi procedure. METHODS: Thirty patients hospitalised for a major depressive episode were filmed at T1 (first week in hospital) and at T2 (2 weeks later) during a 5 min specific interview. The Hamilton Depressive Rating Scale and the Symptom Check List were also rated. Eleven psychiatrists rated these videos using either the usual CGI response format or an improved response format, with or without a Delphi procedure. RESULTS: The new response format slightly improved (but not significantly) the interrater agreement, the Delphi procedure did not. The best results were obtained when ratings by 4 independent raters were averaged. In this situation, intraclass correlation coefficients were about 0.9. CONCLUSION: The Clinical Global Impression is a useful approach in psychiatry since it apprehends patients in their entirety. This study shows that it is possible to quantify such Impressions with a high level of interrater agreement.

Joachim Cordes - One of the best experts on this subject based on the ideXlab platform.

  • Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on Clinical Global Impression in chronic schizophrenia.
    Psychiatry Research-neuroimaging, 2010
    Co-Authors: Joachim Cordes, Johanna Thünker, Marcus W. Agelink, M. Arends, Arian Mobascher, Thomas Wobrock, Thomas Schneider-axmann, Jürgen Brinkmeyer, Margarethe Mittrach, Gunnar Regenbrecht
    Abstract:

    Abstract We conducted a randomized, sham-controlled repetitive transcranial magnetic stimulation (rTMS) study in chronic schizophrenia in-patients ( n =35) to evaluate the therapeutic efficacy of 10 Hz stimulation. Patients, who were on stable antipsychotic treatment, were randomly assigned to the active or sham condition. In the active rTMS group, ten sessions with a total of 10,000 stimuli were applied over the left dorsolateral prefrontal cortex at 110% of motor threshold. The sham group received corresponding sham stimulation. Clinical improvement was measured by the Clinical Global Impression scale (primary outcome measure), the Global Assessment of Functioning Scale (GAF) and the Positive and Negative Symptom Scale (PANSS; secondary outcome measures). Between-group comparisons revealed no significant differences in Clinical outcome variables. Only a subgroup of patients with pronounced negative symptoms developed some Clinical improvement as indicated by significant changes in the GAF-scale. Besides there is some evidence for a more favourable Clinical outcome within this subgroup after rTMS in the CGI-S and PANSS negative scale, too. In line with earlier investigations, our results suggest a moderate — potentially Clinically relevant — treatment effect of prefrontal 10 Hz rTMS stimulation in chronic patients. However, in our study this beneficial effect was restricted to subjects with pronounced negative symptoms. Clinical trial registration information ClinicalTrial.gov Identifier: NCT00169689, http://www.Clinicaltrials.gov.

  • Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on Clinical Global Impression in chronic schizophrenia.
    Psychiatry research, 2010
    Co-Authors: Joachim Cordes, Johanna Thünker, Marcus W. Agelink, M. Arends, Arian Mobascher, Thomas Wobrock, Thomas Schneider-axmann, Jürgen Brinkmeyer, Margarethe Mittrach, Gunnar Regenbrecht
    Abstract:

    We conducted a randomized, sham-controlled repetitive transcranial magnetic stimulation (rTMS) study in chronic schizophrenia in-patients (n=35) to evaluate the therapeutic efficacy of 10 Hz stimulation. Patients, who were on stable antipsychotic treatment, were randomly assigned to the active or sham condition. In the active rTMS group, ten sessions with a total of 10,000 stimuli were applied over the left dorsolateral prefrontal cortex at 110% of motor threshold. The sham group received corresponding sham stimulation. Clinical improvement was measured by the Clinical Global Impression scale (primary outcome measure), the Global Assessment of Functioning Scale (GAF) and the Positive and Negative Symptom Scale (PANSS; secondary outcome measures). Between-group comparisons revealed no significant differences in Clinical outcome variables. Only a subgroup of patients with pronounced negative symptoms developed some Clinical improvement as indicated by significant changes in the GAF-scale. Besides there is some evidence for a more favourable Clinical outcome within this subgroup after rTMS in the CGI-S and PANSS negative scale, too. In line with earlier investigations, our results suggest a moderate - potentially Clinically relevant - treatment effect of prefrontal 10 Hz rTMS stimulation in chronic patients. However, in our study this beneficial effect was restricted to subjects with pronounced negative symptoms. ClinicalTrial.gov Identifier: NCT00169689, http://www.Clinicaltrials.gov. Copyright 2009 Elsevier Ltd. All rights reserved.

F Mandel - One of the best experts on this subject based on the ideXlab platform.

  • Clinical Global Impression of improvement cgi i as a valid proxy measure for remission in schizophrenia analyses of ziprasidone Clinical study data
    Schizophrenia Research, 2011
    Co-Authors: Prakash S Masand, Cedric Ogorman, F Mandel
    Abstract:

    Abstract Objective To determine the degree to which a proxy measure of remission in schizophrenia correlates with the criteria identified by the Remission in Schizophrenia Working Group, and how well early treatment response to ziprasidone predicts remission. Methods Data from 10 ziprasidone studies were analyzed to determine rates of remission achieved with ziprasidone using a remission definition of Clinical Global Impression of Improvement (CGI-I) of 1, and compared with rates of remission achieved using the remission working group criteria. Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores were then investigated as predictors of remission. Results A CGI-I score of 1 correlated with the remission criteria developed by the remission working group. In the combined ziprasidone arms, BPRS scores at Weeks 1, 3, and 4 successfully predicted PANSS remission (p  Conclusion The findings show a correlation between Clinical and research scales (remission working group criteria) for the assessment of remission in schizophrenia. This proxy measure for the assessment of remission should be easy to apply in a Clinical setting and facilitates the prediction of remission in schizophrenia.

  • Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone Clinical study data
    Schizophrenia Research, 2010
    Co-Authors: Prakash S Masand, Cedric O'gorman, F Mandel
    Abstract:

    Abstract Objective To determine the degree to which a proxy measure of remission in schizophrenia correlates with the criteria identified by the Remission in Schizophrenia Working Group, and how well early treatment response to ziprasidone predicts remission. Methods Data from 10 ziprasidone studies were analyzed to determine rates of remission achieved with ziprasidone using a remission definition of Clinical Global Impression of Improvement (CGI-I) of 1, and compared with rates of remission achieved using the remission working group criteria. Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores were then investigated as predictors of remission. Results A CGI-I score of 1 correlated with the remission criteria developed by the remission working group. In the combined ziprasidone arms, BPRS scores at Weeks 1, 3, and 4 successfully predicted PANSS remission ( p p p p  = 0.02) at study endpoint. A CGI-I score of 1 or 2 at Week 1 also successfully predicted remission in schizophrenia. Conclusion The findings show a correlation between Clinical and research scales (remission working group criteria) for the assessment of remission in schizophrenia. This proxy measure for the assessment of remission should be easy to apply in a Clinical setting and facilitates the prediction of remission in schizophrenia.

Prakash S Masand - One of the best experts on this subject based on the ideXlab platform.

  • Clinical Global Impression of improvement cgi i as a valid proxy measure for remission in schizophrenia analyses of ziprasidone Clinical study data
    Schizophrenia Research, 2011
    Co-Authors: Prakash S Masand, Cedric Ogorman, F Mandel
    Abstract:

    Abstract Objective To determine the degree to which a proxy measure of remission in schizophrenia correlates with the criteria identified by the Remission in Schizophrenia Working Group, and how well early treatment response to ziprasidone predicts remission. Methods Data from 10 ziprasidone studies were analyzed to determine rates of remission achieved with ziprasidone using a remission definition of Clinical Global Impression of Improvement (CGI-I) of 1, and compared with rates of remission achieved using the remission working group criteria. Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores were then investigated as predictors of remission. Results A CGI-I score of 1 correlated with the remission criteria developed by the remission working group. In the combined ziprasidone arms, BPRS scores at Weeks 1, 3, and 4 successfully predicted PANSS remission (p  Conclusion The findings show a correlation between Clinical and research scales (remission working group criteria) for the assessment of remission in schizophrenia. This proxy measure for the assessment of remission should be easy to apply in a Clinical setting and facilitates the prediction of remission in schizophrenia.

  • Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone Clinical study data
    Schizophrenia Research, 2010
    Co-Authors: Prakash S Masand, Cedric O'gorman, F Mandel
    Abstract:

    Abstract Objective To determine the degree to which a proxy measure of remission in schizophrenia correlates with the criteria identified by the Remission in Schizophrenia Working Group, and how well early treatment response to ziprasidone predicts remission. Methods Data from 10 ziprasidone studies were analyzed to determine rates of remission achieved with ziprasidone using a remission definition of Clinical Global Impression of Improvement (CGI-I) of 1, and compared with rates of remission achieved using the remission working group criteria. Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores were then investigated as predictors of remission. Results A CGI-I score of 1 correlated with the remission criteria developed by the remission working group. In the combined ziprasidone arms, BPRS scores at Weeks 1, 3, and 4 successfully predicted PANSS remission ( p p p p  = 0.02) at study endpoint. A CGI-I score of 1 or 2 at Week 1 also successfully predicted remission in schizophrenia. Conclusion The findings show a correlation between Clinical and research scales (remission working group criteria) for the assessment of remission in schizophrenia. This proxy measure for the assessment of remission should be easy to apply in a Clinical setting and facilitates the prediction of remission in schizophrenia.

  • Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone Clinical study data.
    Schizophrenia research, 2010
    Co-Authors: Prakash S Masand, Cedric O'gorman, Francine S Mandel
    Abstract:

    To determine the degree to which a proxy measure of remission in schizophrenia correlates with the criteria identified by the Remission in Schizophrenia Working Group, and how well early treatment response to ziprasidone predicts remission. Data from 10 ziprasidone studies were analyzed to determine rates of remission achieved with ziprasidone using a remission definition of Clinical Global Impression of Improvement (CGI-I) of 1, and compared with rates of remission achieved using the remission working group criteria. Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) scores were then investigated as predictors of remission. A CGI-I score of 1 correlated with the remission criteria developed by the remission working group. In the combined ziprasidone arms, BPRS scores at Weeks 1, 3, and 4 successfully predicted PANSS remission (p<0.01) and BPRS remission (p<0.0001) at study endpoint (44-196weeks). PANSS scores (at Weeks 1, 3, and 4) successfully predicted PANSS remission (p<0.01) at study endpoint. PANSS scores at Week 3 successfully predicted BPRS remission (p=0.02) at study endpoint. A CGI-I score of 1 or 2 at Week 1 also successfully predicted remission in schizophrenia. The findings show a correlation between Clinical and research scales (remission working group criteria) for the assessment of remission in schizophrenia. This proxy measure for the assessment of remission should be easy to apply in a Clinical setting and facilitates the prediction of remission in schizophrenia. Copyright © 2010 Elsevier B.V. All rights reserved.